<qa>  What is the name of the IV that patients receive?ARM II: Patients receive Anti-PD-1 nivolumab IV over 60 minutes on days 1 and 15 and urelumab IV on day 1. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. 